Abiopharma

News list

Vir Biotechnology (VIR)

Event
Oct. 04, 2022, 12:23 UTC

(10% Negative) Vir Biotechnology, Inc. (VIR) Announces Delay in Administration Development Timeline Due to Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text

News bot Oct. 3, 2025, 8:28 a.m.

📋 Vir Biotechnology, Inc. (VIR) - Clinical Trial Update

Filing Date: 2022-10-04

Accepted: 2022-10-04 08:23:56

Event Type: Clinical Trial Update

Event Details:

Vir Biotechnology (VIR) Announces Clinical Trial Update Vir Biotechnology (VIR) provided an update on its clinical development programs. Clinical Development Highlights:

Drug Program: Administration, initially
Update Type: Trial Timeline Adjustment
Primary Factors: Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
Collaboration: BARDA’s
- anticipated in mid-2023
- targeting COVID-19, hepatitis B and hepatitis D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995

🔬 Clinical Development Pipeline (Vir Biotechnology, Inc.):

Product	Type	Development Stage	Therapeutic Area	Source
Proton pump inhibitor	DRUG	Preclinical	Glioblastoma	ClinicalTrials.gov
Hydrocortisone	DRUG	Preclinical	Glioblastoma	ClinicalTrials.gov
AVM0703	DRUG	Preclinical	Glioblastoma	ClinicalTrials.gov
AC699	DRUG	Phase PHASE1	Breast Cancer	ClinicalTrials.gov
AC676	DRUG	Phase PHASE1	Relapsed/Refractory B-cell Malignancies	ClinicalTrials.gov

💼 Business Developments:

Partnership
Acquisition: Not available
Licensing: Not available
Regulatory Approval
Executive Changes: Not available

Structured Data:

Company Name: Vir Biotechnology
CIK: 0001706431
Ticker Symbol: VIR
Period End Date: 2022-09-28
Document Type: 8-K